MDC-CAR-BCMA-001

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameMDC-CAR-BCMA-001

Drug Alias NameAnti-BCMA-Targeting CAR T-Cell Therapy (Technische Universitat Dresden/German Cancer Research Center)MDC-CAR-BCMA-001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionT lymphocytes stimulantsImmunostimulants

TargetsUpdating

Therapy Area/IndicationsMultiple MyelomaLymphoma, Large B-Cell, Diffuse

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTechnische Universitat Dresden

China Registration ClassN/A

Develop Information

Active CompaniesGerman Cancer Research Center (Dkfz)Technische Universitat Dresden

Inactive CompaniesN/A

Active IndicationsMultiple MyelomaLymphoma, Large B-Cell, Diffuse

Inactive IndicationsN/A

Other Information

ATC CodeN/A